comparemela.com

Latest Breaking News On - University of the witwatersrand in gauteng - Page 1 : comparemela.com

Severe Outcomes Declined During Omicron in South Africa

17 March 2021 Coronavirus Charts and News: Is Facebook A Worthy Judge of Medical Info? IRS Plans To Delay Tax Filing Deadline To Mid-May Two California COVID Strains Are Variants of Concern

The U.S. new cases 7-day rolling average are 4.8 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 15.2 % LOWER than the rolling average one week ago. Today s posts include: U.S. Coronavirus New Cases are 54,434 U.S. Coronavirus deaths are at 1,245 U.S. Coronavirus immunizations have been administered to 33.1 % of the population The 7-day rolling average rate of growth of the pandemic shows new cases worsened and deaths improved What we know about India s Covid-19 vaccine AstraZeneca Vax Flops Against South African Variant in Early Trial Some long-haul covid-19 patients say their symptoms are subsiding after getting vaccines

AstraZeneca Vax Flops Against South African Variant in Early Trial

email article AstraZeneca s COVID-19 vaccine was not protective against mild-to-moderate disease from either the so-called South African variant (B.1.351) or the wild type virus, an interim analysis of phase Ib/II data found. Overall vaccine efficacy against mild-to-moderate COVID-19 in South Africa was 21.9% (95% CI -49.9 to 59.8), and efficacy against B.1.351 was 10.4% (95% CI -76.8 to 54.8), reported Shabir Madhi, PhD, of University of the Witwatersrand in Gauteng, South Africa, and colleagues, in the Previously, pooled efficacy data on the AstraZeneca vaccine from the U.K., Brazil, and South Africa, prior to B.1.351 s emergence, showed overall efficacy of 66.7% (95.8% CI 57.4-74.0), as well as 74.6% efficacy against the so-called U.K. variant, B.1.1.7.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.